Analysts and Calls -- Lehman Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- Lehman

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	6/10/2003 2:55:35 PM
From: Icebrg	of 30

ICOS initiated with "overweight" -update Tuesday, June 10, 2003 10:27:01 AM ET Lehman Brothers NEW YORK, June 10 (New Ratings) — Analyst Jim Birchenough of Lehman Brothers initiates coverage of ICOS Corporation (ICOS) with an "overweight" rating. The target price is set to $53. The analyst expects ICOS Corporation's stock to benefit significantly from the robust sales potential of the company's upcoming erectile dysfunction drug, Cialis. Lehman Brothers anticipates a rapid expansion potential for the male erectile dysfunction market, following the launches of Cialis and GSK/Bayer's Levitra in 2H03.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next